These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23799913)

  • 1. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
    Limone BL; Sidovar MF; Coleman CI
    Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
    Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
    Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
    Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
    Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalfampridine extended release: in multiple sclerosis.
    Chwieduk CM; Keating GM
    CNS Drugs; 2010 Oct; 24(10):883-91. PubMed ID: 20839898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
    Coleman CI; Sobieraj DM; Marinucci LN
    Curr Med Res Opin; 2012 Jan; 28(1):49-56. PubMed ID: 22073939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
    Goodman AD; Brown TR; Edwards KR; Krupp LB; Schapiro RT; Cohen R; Marinucci LN; Blight AR;
    Ann Neurol; 2010 Oct; 68(4):494-502. PubMed ID: 20976768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
    Cameron MH; Fitzpatrick M; Overs S; Murchison C; Manning J; Whitham R
    Mult Scler; 2014 May; 20(6):733-8. PubMed ID: 24099749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
    Blight AR; Henney HR; Cohen R
    Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J
    Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
    Cornblath DR; Bienen EJ; Blight AR
    Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Macdonell R; Nagels G; Laplaud DA; Pozzilli C; de Jong B; Martins da Silva A; Nicholas R; Lechner-Scott J; Gaebler JA; Agarwal S; Wang P; Yeh M; Hovenden M; Soelberg Sørensen P
    Mult Scler; 2016 Jun; 22(7):944-54. PubMed ID: 26447066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
    CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program.
    Crayton H; Sidovar M; Wulf S; Guo A
    Patient; 2015 Jun; 8(3):283-91. PubMed ID: 25475652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
    Hobart J; Blight AR; Goodman A; Lynn F; Putzki N
    Neurology; 2013 Apr; 80(16):1509-17. PubMed ID: 23535489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
    Lo AC; Ruiz JA; Koenig CM; Anderson BM; Olson KM; Triche EW
    J Neurol Sci; 2015 Sep; 356(1-2):77-82. PubMed ID: 26139339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalfampridine effects on cognition, fatigue, and dexterity.
    Korsen M; Kunz R; Schminke U; Runge U; Kohlmann T; Dressel A
    Brain Behav; 2017 Jan; 7(1):e00559. PubMed ID: 28127507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study.
    Skov CD; Sørensen CB; Thorning M; Lambertsen KL; Frich LH; Jensen HB; Holsgaard-Larsen A; Nielsen HH
    Mult Scler Relat Disord; 2022 Oct; 66():104034. PubMed ID: 35843140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.
    Rabadi MH; Kreymborg K; Vincent AS
    Drugs R D; 2013 Sep; 13(3):175-81. PubMed ID: 23873597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
    Dunn J; Blight A
    Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.